RhumbLine Advisers
CATX icon

RhumbLine Advisers’s Perspective Therapeutics CATX Stock Holding History

RhumbLine Advisers’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
77,090
+519
+0.7% +$2.19K ﹤0.01% 2882
2025
Q4 		$211K Sell
76,571
-8,234
-10% -$23.5K ﹤0.01% 3158
2025
Q3 		$291K Buy
84,805
+1,555
+2% +$5.67K ﹤0.01% 3021
2025
Q2 		$286K Sell
83,250
-14,912
-15% -$39.4K ﹤0.01% 3011
2025
Q1 		$209K Buy
98,162
+3,170
+3% +$9.51K ﹤0.01% 3082
2024
Q4 		$303K Buy
94,992
+4,075
+4% +$33.3K ﹤0.01% 2979
2024
Q3 		$1.21M Buy
90,917
+27,747
+44% +$369K ﹤0.01% 2164
2024
Q2 		$630K Buy
+63,170
New +$913K ﹤0.01% 2508

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's CATX Position: Q1 2026 in Review

RhumbLine Advisers increased its Perspective Therapeutics (CATX) stake by 0.68% in Q1 2026, buying an estimated $2.19K and bringing the position to 77,090 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #2882.

RhumbLine Advisers first reported a position in CATX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.21M in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • RhumbLine Advisers held 77,090 shares of Perspective Therapeutics worth $321K as of Q1 2026.
  • RhumbLine Advisers bought 519 Perspective Therapeutics shares in Q1 2026, an estimated $2.19K.
  • Perspective Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2882 holding.
  • RhumbLine Advisers first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • RhumbLine Advisers's Perspective Therapeutics position peaked at $1.21M in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.